Seattle Genetics was founded by Clay Siegall in 1998. He acts as the company’s Chairman of the Board and Chief Executive Officer. He is a career scientist who is passionate about cancer research. He is an emblem of scientific innovation within the cancer research community, and he has created new drug development practices that have been employed in rigorous scientific research on cancer. Seattle Genetics is an industry leader in the development of antibody drug conjugates. It has received approval from the FDA for its products and has put the famous drug known as ADCETRIS on the market. Under Clay Siegall’s leadership, Seattle Genetics formed a strategic partnership with Takeda Pharmaceutical Company. This partnership has made it possible for Seattle Genetics to help patients in more than 60 countries around the world. The company continues to innovate new products for the treatment of cancer and is currently developing new antibody-drug conjugate products.
Clay Siegall has driven Seattle Genetics to enter into various strategic licenses for its proprietary cancer treatment technology. AbbVie, GlaxoSmithKline, Pfizer, and Genentech are some of the companies it works with. More than $325 million have been generated from these licenses at this point in time. This is because Clay’s company has developed over 20 proprietary technologies in the area of cancer research. Investors see great potential in Seattle Genetics and they have invested more than a billion dollars in the company.
Clay Siegall began his education at the University of Maryland where he earned a B.S. in Zoology. He loved science and wanted to learn more about how he could use it to help people, so he went on to George Washington University where he earned a Ph.D. in Genetics. Since that time, Clay has continued to absorb interdisciplinary knowledge that would help him in the fight against cancer. His contributions to science were recognized by the University of Maryland in 2013. It awarded him the prize for Alumnus of the Year for Computer, Math, and Natural Sciences.